NasdaqGS:ENTA
NasdaqGS:ENTABiotechs

Enanta Pharmaceuticals (ENTA) Is Up 33.3% After Positive Phase 2b RSV Results Propel Zelicapavir Forward

In late September 2025, Enanta Pharmaceuticals announced positive topline results from its Phase 2b trial of zelicapavir for treating respiratory syncytial virus (RSV) in high-risk adults, observing faster symptom resolution and a lower hospitalization rate despite not meeting the trial's primary endpoint. This proof-of-concept success provides the company with clear support to advance zelicapavir into Phase 3 development, potentially addressing significant unmet needs in the RSV market for...
NasdaqCM:HLP
NasdaqCM:HLPMetals and Mining

Hongli Group (NasdaqCM:HLP) Swings to Profit, Premium Valuation Fuels Market Skepticism

Hongli Group (NasdaqCM:HLP) has just swung to profitability, a notable shift given its challenging track record. Over the last five years, the company’s earnings have declined sharply at an average rate of 49.9% per year, and despite this new profit milestone, the historical headwinds remain evident for investors assessing future growth prospects. See our full analysis for Hongli Group. The next section looks beyond the numbers, putting Hongli Group’s latest results in the context of how...